Skip to Content

Generic Rapamune Availability

Rapamune is a brand name of sirolimus, approved by the FDA in the following formulation(s):

RAPAMUNE (sirolimus - solution;oral)

  • Manufacturer: PF PRISM CV
    Approval date: September 15, 1999
    Strength(s): 1MG/ML [RLD]

RAPAMUNE (sirolimus - tablet;oral)

  • Manufacturer: PF PRISM CV
    Approval date: August 25, 2000
    Strength(s): 1MG [RLD] [AB]
  • Manufacturer: PF PRISM CV
    Approval date: August 22, 2002
    Strength(s): 2MG [RLD] [AB]
  • Manufacturer: PF PRISM CV
    Approval date: February 23, 2004
    Strength(s): 5MG [RLD]
  • Manufacturer: PF PRISM CV
    Approval date: January 25, 2010
    Strength(s): 0.5MG [RLD] [AB]

Has a generic version of Rapamune been approved?

A generic version of Rapamune has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Rapamune and have been approved by the FDA:

sirolimus tablet;oral

  • Manufacturer: DR REDDYS LABS LTD
    Approval date: October 27, 2014
    Strength(s): 1MG [AB], 2MG [AB]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: January 8, 2014
    Strength(s): 0.5MG [AB]

Note: No generic formulation of the following product is available.

  • sirolimus - solution;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rapamune. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Rapamycin formulations for oral administration
    Patent 5,989,591
    Issued: November 23, 1999
    Inventor(s): Nagi; Arwinder S.
    Assignee(s): American Home Products Corporation
    This invention provides rapamycin solid dosage unit which comprises a core and a sugar overcoat, said sugar overcoat comprising rapamycin, one or more surface modifying agents, one or more sugars, and optionally one or more binders.
    Patent expiration dates:
    • March 11, 2018
      Drug product
    • September 11, 2018
      Pediatric exclusivity

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 28, 2022 - ORPHAN DRUG EXCLUSIVITY
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.